
Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.
Unpublished, interim phase 3 data show an approximate 50% reduction in hospitalizations and deaths versus placebo. Merck is expediting FDA application for the antiviral drug.
This type of stewardship is a means of reducing unnecessary testing, getting the appropriate diagnosis more efficiently, and getting patients the appropriate therapy in a timely manner.
In the primary efficacy analysis, the risk of developing symptomatic COVID 19 was reduced by 77% with AZD7442.
The study author of the late-breaking IDWeek findings discusses what the new data mean for using the antiviral to reduce COVID-19 burden.
A survey found most healthcare professionals would clear an asymptomatic patient with a positive PCR test if the patient met other criteria.
In a study looking at one urban South Florida hospital, the pandemic negatively impacted testing.
A study found disproportionately higher COVID-19 cases in Black and Hispanic people with HIV across the US.
A study’s findings support the use of the therapy earlier in the course of COVID-19 in hospitalized patients.
Orange County, CA nursing homes that partook in either universal decolonization or prevention training had significantly fewer staff and resident COVID-19 cases than nursing homes that did not.
During the pandemic, hospitalists prescribing patterns changed, reflecting new data, clinical experience, and the introduction of new therapies.
Investigators saw vastly higher rates of hospitalization and mortality for rural populations over urban even after adjusting the results for various factors.
The Infectious Diseases Society of America’s (IDSA) 2017 guideline saw an increase in using vancomycin as a first line therapy for Clostridioides difficile (CDI).
A team from a tertiary center in the Middle East used a multidisciplinary approach to increase immunization.
In research presented virtually at IDWeek 2021, investigators with the Centers for Disease Control and Prevention (CDC) conducted a review of nursing home antibiotic stewardship citation deficiencies in order to improve implementation.
In newly hospitalized hypoxic patients with COVID-19, the monoclonal antibody significantly improved survival without invasive mechanical ventilation compared with placebo and available treatments, according to phase 3 trial results.
Ferring is presenting data from five studies at this week’s IDWeek about its investigational biotherapeutic, RBX2660, being studied for this problematic bacterium.
Mortality rates of children with HIV may be underreported due to lack of patient follow-up and the usage of routine program data.
A new study breaks down the risk prediction of death or hospitalization related to COVID-19 in adults following their vaccination.
“Compared to the pre-COVID period, the odds ratio for CVD encounters was nearly doubled in each post-COVID period from 31 to 90 days post onset,” Brian Agan, MD, deputy science director and HIV research director of the Infectious Disease Clinical Research Program at USU/HJF and presenting author, told Contagion®.
Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.
Research suggests studies should adjust their cohort comparison group to account for demographics most represented by people living with HIV.
The companies will be seeking emergency authorization for a lighter-dose mRNA vaccine for children aged 5 to <12 years old.
Data finds low risk for anaphylaxis, myocarditis, and other potential complications.
The Fenway Institute is hosting its upcoming Advancing Excellence in Transgender Health conference. The program will include education on transgender medical care as well as how clinicians and people within this community can interact and the former can understand the latter’s needs when it comes to preventative and acute care.
England has been meeting and exceeding its HIV diagnosis and treatment goals set by UNAIDS.
The protective effect remained strong through the 18- and 24-month follow-up periods, the study authors said.
Extended findings from blinded mRNA-1273 vaccine pivotal trial include efficacy across subgroups, including elderly and with coexisting conditions.
Parentless youth living on the streets had the highest rates of HIV and death, but extended-family living situations were not necessarily better than institutional care.
The emergence of this fungal infection remains mysterious as the world experiences more outbreaks.
Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.